Pegylated recombinant human hyaluronidase companion diagnostic - Halozyme

Drug Profile

Pegylated recombinant human hyaluronidase companion diagnostic - Halozyme

Alternative Names: PEG PH20 companion diagnostic - Halozyme; PEG rHuPH-20 companion diagnostic - Halozyme; Pegylated rHuPH20 companion diagnostic - Halozyme

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Halozyme Therapeutics
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pancreatic cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Pancreatic-cancer(Diagnosis) in Russia
  • 09 May 2016 US FDA approves Investigational Device Exemption application for Pegylated recombinant human hyaluronidase companion diagnostic for diagnosis of patients with Pancreatic cancer in a phase III trial
  • 29 Feb 2016 Ventana Medical Systems files an IDE application with the US FDA for diagnosis of patients with Pancreatic cancer for a phase III trial
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top